The neuromuscular disease community received encouraging news this week as Edgewise Therapeutics announced the sale of sevasemten and its Becker and Duchenne muscular dystrophy programs to Servier, a global pharmaceutical company with […]
Updated: December 4, 2025 From Belief to Breakthrough: Celebrating Avidity’s Potential Acquisition by Novartis In 2018, CureDuchenne made a bold investment in a promising company with an idea that could […]
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing […]
CureDuchenne Clinic within the Neuromuscular Program at CHOC Will Expand Access to Exceptional Care, Deliver Cutting-Edge Treatments, and Drive Innovative Research Newport Beach, CA– March 3, 2025– CureDuchenne, a global […]
By Debra Miller, Founder and CEO of CureDuchenne Duchenne International Outreach: Bridging Gaps in Duchenne Care At CureDuchenne, we have always believed in the transformative power of connection—the kind of […]
By Debra Miller, Founder and CEO of CureDuchenne I’m honored to share two transformative events that embody both the resilience of the human spirit and the strength of our community: […]
Read a message from our founder and CEO The recently released award-winning Netflix documentary “The Remarkable Life of Ibelin,”* highlights the life of Mats Steen, a Norwegian World of Warcraft […]
Genethon reported positive results from its AAV-microdystrophin treatment trial in Europe. The three participants receiving the study’s higher dose (3×1013vg/kg) showed that an average of 54% of muscle fibers were […]
See the previous update from June 22, 2023 here FDA Grants Traditional Approval for Ambulatory Individuals and Accelerated Approval for Non-Ambulatory Individuals to Sarepta Therapeutics’ ELEVIDYS Gene Therapy for Duchenne […]
